Acadia Pharmaceuticals Inc. (ACAD)

Price$21.52

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-21.35%

Price vs S&P 500 (4W)-6.29%

VGM Score46.81

Market Capitalization$3.64B

P/E Ratio (Annual)9.31x

All Metrics

P/CF (Annual)33.13x

Book Value / Share (Quarterly)$7.29

P/TBV (Annual)4.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.83%

Cash Flow / Share (Quarterly)$0.66

Price vs S&P 500 (YTD)-29.84%

Gross Margin (TTM)91.47%

Net Profit Margin (TTM)34.30%

EPS (TTM)$2.19

10-Day Avg Trading Volume1.45M

EPS Excl Extra (TTM)$2.19

Revenue Growth (5Y)15.68%

EPS (Annual)$2.30

ROI (Annual)31.86%

Gross Margin (Annual)91.69%

Net Profit Margin (5Y Avg)-4.95%

Cash / Share (Quarterly)$4.98

P/E Basic Excl Extra (TTM)9.69x

Revenue Growth QoQ (YoY)9.39%

P/E Normalized (Annual)9.31x

ROA (Last FY)25.00%

Revenue Growth TTM (YoY)-13.64%

EBITD / Share (TTM)$0.48

ROE (5Y Avg)3.38%

Operating Margin (TTM)7.39%

Cash Flow / Share (Annual)$0.04

P/B Ratio2.92x

P/B Ratio (Quarterly)3.04x

Net Income / Employee (Annual)$491,200

EV / Revenue (TTM)3.06x

Net Interest Coverage (TTM)-30.69x

ROA (TTM)26.24%

EPS Growth QoQ (YoY)-81.36%

EV / EBITDA (TTM)41.02x

EPS Incl Extra (Annual)$2.30

Current Ratio (Annual)3.83x

Quick Ratio (Quarterly)3.27x

3-Month Avg Trading Volume1.76M

52-Week Price Return-2.83%

EV / Free Cash Flow (Annual)532.11x

P/E Incl Extra (TTM)9.69x

Revenue / Employee (TTM)$1,375,900

Tangible BV / Share (Quarterly)$6.67

P/S Ratio (Annual)3.40x

Asset Turnover (Annual)0.69x

52-Week High$28.35

Operating Margin (5Y Avg)-10.93%

EPS Excl Extra (Annual)$2.30

Tangible BV CAGR (5Y)9.93%

26-Week Price Return-5.41%

Quick Ratio (Annual)3.49x

13-Week Price Return-12.09%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.59x

Enterprise Value$3.36B

Revenue / Share Growth (5Y)14.54%

Asset Turnover (TTM)0.77x

Book Value / Share Growth (5Y)23.88%

Revenue / Employee (Annual)$1,346,100

Inventory Turnover (Annual)3.14x

Pretax Margin (Annual)12.96%

Cash / Share (Annual)$4.81

3-Month Return Std Dev39.34%

Gross Margin (5Y Avg)94.35%

Net Income / Employee (TTM)$471,900

ROE (Last FY)31.86%

Net Interest Coverage (Annual)-30.69x

EPS Basic Excl Extra (Annual)$2.30

P/FCF (TTM)21.88x

Receivables Turnover (TTM)9.09x

EV / Free Cash Flow (TTM)29.55x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$2.19

Receivables Turnover (Annual)9.73x

ROI (TTM)35.65%

P/S Ratio (TTM)3.32x

Pretax Margin (5Y Avg)-8.60%

Revenue / Share (Annual)$6.31

Tangible BV / Share (Annual)$6.57

Forward P/E38.47x

Price vs S&P 500 (52W)-31.03%

P/E Ratio (TTM)9.69x

EPS Growth TTM (YoY)87.54%

Year-to-Date Return-18.91%

5-Day Price Return2.65%

EPS Normalized (Annual)$2.30

ROA (5Y Avg)0.90%

Net Profit Margin (Annual)36.49%

Month-to-Date Return-3.52%

Cash Flow / Share (TTM)$-0.88

EBITD / Share (Annual)$0.62

Operating Margin (Annual)9.78%

LT Debt / Equity (Annual)0.01x

P/CF (TTM)29.47x

ROI (5Y Avg)3.38%

P/E Excl Extra (TTM)9.69x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$2.19

P/TBV (Quarterly)3.32x

P/B Ratio (Annual)3.68x

Inventory Turnover (TTM)3.43x

Pretax Margin (TTM)10.51%

Book Value / Share (Annual)$7.21

Price vs S&P 500 (13W)-21.84%

Beta0.84x

P/FCF (Annual)576.85x

Revenue / Share (TTM)$6.34

ROE (TTM)35.65%

52-Week Low$19.69

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.02est. 0.06

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.85

3.93

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACADAcadia Pharmaceuticals Inc.	C	C	C	$21.52
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises in neurological and rare diseases. Its neurological franchise is anchored by NUPLAZID (pimavanserin), the first FDA-approved treatment for Parkinson's disease psychosis, while its rare disease franchise is built on DAYBUE, the first FDA-approved treatment for Rett syndrome. The company's clinical pipeline includes programs targeting Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and other neurological disorders.